Perceptive Advisors portfolio · Q1 2026
Perceptive Advisors LLC · CIK 0001224962 ·13F filings on SEC EDGAR
In Q1 2026, Perceptive Advisors LLC reported 94 positions worth $5.1B. Its largest holding was PRAX at 12.8% of the portfolio, and the top 10 made up 51%. Its largest new position was MRNA ($50.8M), and it sold out of XBI.
- NEW 20
- ADD 23
- REDUCE 33
- EXIT 42
Portfolio map
Each box is a position sized by its value. Color shows the change in shares from the previous quarter. The smallest 54 positions are grouped as one box.
Portfolio history
Q4 2025 to Q1 2026, 2 quarters
Weight of the largest holdings
The 7 holdings with the highest weight in any quarter shown, stacked with all others to 100%.
Holding timeline
Shade shows the weight in each quarter. A blank cell means the holding was not reported that quarter.
Holdings
Click a holding to see its price chart with the quarters the investor bought or sold.
| Name | Weight | Avg. cost (est.) | Latest price | Gain/loss | Value |
|---|---|---|---|---|---|
PRAX PRAXIS PRECISION MEDICINES I | 12.82% | $112.81 | $291.23 | +158.2% | $592.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CELC CELCUITY INC | 6.97% | $36.00 | $79.52 | +120.9% | $248.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
04351P101 ASCENDIS PHARMA A/S | 6.84% | $191.21 | $228.73 | +19.6% | $350.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ROIV ROIVANT SCIENCES LTD | 4.48% | $14.52 | $36.57 | +151.8% | $303M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CNTA CENTESSA PHARMACEUTICALS LTD | 4.08% | $28.79 | $39.72 | +38.0% | $208.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RYTM RHYTHM PHARMACEUTICALS INC | 4.03% | $100.66 | $95.22 | -5.4% | $226M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SYRE SPYRE THERAPEUTICS INC | 3.73% | $32.47 | $89.03 | +174.2% | $336.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NUVL NUVALENT INC-A | 3.16% | $51.19 | $123.50 | +141.2% | $195.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EWTX EDGEWISE THERAPEUTICS INC | 2.72% | $21.59 | $40.60 | +88.0% | $179.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PTGX PROTAGONIST THERAPEUTICS INC | 2.54% | $43.67 | $140.89 | +222.6% | $173.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
APGE APOGEE THERAPEUTICS INC | 2.53% | $48.89 | $132.73 | +171.5% | $204.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TVTX TRAVERE THERAPEUTICS INC | 2.40% | $23.74 | $58.88 | +148.0% | $243.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AMLX AMYLYX PHARMACEUTICALS INC | 2.25% | $4.78 | $29.10 | +508.6% | $241.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IMTX IMMATICS NV | 2.00% | $10.71 | $8.78 | -18.0% | $91.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RLAY RELAY THERAPEUTICS INC | 1.90% | $9.66 | $18.05 | +86.9% | $176M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
INBX INHIBRX BIOSCIENCES INC | 1.90% | $24.45 | $100.08 | +309.4% | $144.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MGTX MEIRAGTX HOLDINGS PLC | 1.75% | $13.24 | $11.00 | -16.9% | $113.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ZYME ZYMEWORKS INC | 1.72% | $17.84 | $26.49 | +48.5% | $93M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SLDB SOLID BIOSCIENCES INC | 1.68% | $6.95 | $7.23 | +4.0% | $86.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DYN DYNE THERAPEUTICS INC | 1.65% | $18.83 | $16.11 | -14.5% | $75.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BCRX BIOCRYST PHARMACEUTICALS INC | 1.38% | $8.79 | $8.33 | -5.2% | $61.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ORKA ORUKA THERAPEUTICS INC | 1.34% | $20.79 | $83.29 | +300.5% | $116.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AORT ARTIVION INC | 1.17% | $20.47 | $34.23 | +67.2% | $56M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NRIX NURIX THERAPEUTICS INC | 1.12% | $16.34 | $23.71 | +45.1% | $88M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.99% | — | — | — | $50.8M | |
NAUT NAUTILUS BIOTECHNOLOGY INC | 0.95% | $6.31 | $1.42 | -77.5% | $17.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CTMX CYTOMX THERAPEUTICS INC | 0.93% | $2.62 | $2.72 | +4.0% | $27.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ANRO ALTO NEUROSCIENCE INC | 0.88% | $17.26 | $25.53 | +47.9% | $51.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
29286M105 ENGENE HOLDINGS INC | 0.78% | $8.24 | $6.81 | -17.4% | $39.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IMVT IMMUNOVANT INC | 0.78% | $24.48 | $33.78 | +38.0% | $54M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ISRG INTUITIVE SURGICAL INC | 0.77% | $468.73 | $406.63 | -13.2% | $34.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IONS IONIS PHARMACEUTICALS INC | 0.74% | $75.09 | $44.65 | -40.5% | $22.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DAWN DAY ONE BIOPHARMACEUTICALS I | 0.74% | $21.44 | $21.44 | 0.0% | $37.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ABVX ABIVAX SA-ADR | 0.72% | $92.50 | $99.02 | +7.0% | $32.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CRVS CORVUS PHARMACEUTICALS INC | 0.66% | $11.42 | $11.52 | +0.9% | $26.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RGEN REPLIGEN CORP | 0.65% | $134.28 | $192.23 | +43.2% | $53.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
JAZZ JAZZ PHARMACEUTICALS PLC | 0.63% | $170.00 | $231.52 | +36.2% | $39.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
36322Q206 DAMORA THERAPEUTICS INC | 0.62% | $25.90 | $26.01 | +0.4% | $31.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
XFOR X4 PHARMACEUTICALS INC | 0.54% | $4.01 | $2.90 | -27.6% | $19.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GH GUARDANT HEALTH INC | 0.54% | $97.58 | $178.36 | +82.8% | $53.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DRUG BRIGHT MINDS BIOSCIENCES INC | 0.54% | $37.59 | $49.82 | +32.5% | $18.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IVVD INVIVYD INC | 0.53% | $2.47 | $0.87 | -64.8% | $18.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SION SIONNA THERAPEUTICS INC | 0.52% | $10.46 | $5.26 | -49.7% | $3.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AXSM AXSOME THERAPEUTICS INC | 0.50% | $82.27 | $184.39 | +124.1% | $27.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RVMD REVOLUTION MEDICINES INC | 0.49% | $97.25 | $205.26 | +111.1% | $53.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SABS SAB BIOTHERAPEUTICS INC | 0.48% | $3.82 | $3.17 | -17.0% | $20.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BLTE BELITE BIO INC - ADR | 0.47% | $149.63 | $169.82 | +13.5% | $25.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TENX TENAX THERAPEUTICS INC | 0.45% | $14.84 | $56.70 | +282.1% | $82.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AXGN AXOGEN INC | 0.45% | $32.73 | $41.92 | +28.1% | $29.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VRDN VIRIDIAN THERAPEUTICS INC | 0.45% | $26.42 | $20.59 | -22.1% | $24.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OBIO ORCHESTRA BIOMED HOLDINGS IN | 0.42% | $10.64 | $6.22 | -41.6% | $31.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RAPP RAPPORT THERAPEUTICS INC | 0.41% | $29.96 | $33.60 | +12.2% | $22.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DBVT DBV TECHNOLOGIES SA-SPON ADR | 0.39% | $20.89 | $11.76 | -43.7% | $11.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LONA LEONABIO INC | 0.37% | $6.49 | $3.57 | -45.0% | $6.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AVR ANTERIS TECHNOLOGIES GLOBAL | 0.37% | $5.56 | $7.77 | +39.6% | $26.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
STRO SUTRO BIOPHARMA INC | 0.35% | $24.91 | $16.11 | -35.3% | $11.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TNGX TANGO THERAPEUTICS INC | 0.33% | $13.26 | $24.95 | +88.1% | $20.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CTNM CONTINEUM THERAPEUTICS INC-A | 0.32% | $14.38 | $13.42 | -6.7% | $16.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.31% | — | — | — | $15.9M | |
PALI PALISADE BIO INC | 0.31% | $2.35 | $1.35 | -42.6% | $12.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OCS OCULIS HOLDING AG | 0.26% | $19.97 | $9.34 | -53.2% | $4.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IRTC IRHYTHM HOLDINGS INC | 0.24% | $171.99 | $113.66 | -33.9% | $11.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ADGM ADAGIO MEDICAL HOLDINGS INC | 0.22% | $2.57 | $0.15 | -94.1% | $1.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EVMN EVOMMUNE INC | 0.20% | $22.99 | $8.26 | -64.1% | $3.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PHAT PHATHOM PHARMACEUTICALS INC | 0.20% | $11.11 | $7.30 | -34.3% | $6.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NMRA NEUMORA THERAPEUTICS INC | 0.19% | $1.95 | $0.60 | -69.4% | $3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OMDA OMADA HEALTH INC | 0.19% | $18.30 | $21.95 | +19.9% | $17.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NBIX NEUROCRINE BIOSCIENCES INC | 0.17% | $132.58* | $141.84 | +7.0% | $9.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BBNX BETA BIONICS INC | 0.17% | $18.64 | $18.98 | +1.8% | $16M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IRD OPUS GENETICS INC | 0.16% | $0.98 | $4.84 | +393.0% | $8.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BLLN BILLIONTOONE INC CL A | 0.14% | $81.24 | $106.44 | +31.0% | $9.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TWST TWIST BIOSCIENCE CORP | 0.14% | $47.52 | $193.24 | +306.6% | $29M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SRZN SURROZEN INC | 0.13% | $29.13 | $32.18 | +10.5% | $7.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AGMB AGOMAB THERAPEUTICS NV | 0.12% | $10.49 | $11.10 | +5.8% | $6.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EOLS EVOLUS INC | 0.10% | $4.11 | $8.00 | +94.6% | $10.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
COGT COGENT BIOSCIENCES INC | 0.09% | $35.52 | $32.02 | -9.9% | $3.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OCULCall OCULAR THERAPEUTIX INC | 0.08% | — | — | — | $4.2M |
ADMA ADMA BIOLOGICS INC | 0.08% | $8.43 | $10.03 | +19.0% | $4.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IKT INHIBIKASE THERAPEUTICS INC | 0.08% | $3.25 | $2.06 | -36.8% | $4.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CBIO CRESCENT BIOPHARMA INC | 0.07% | $16.14 | $14.59 | -9.6% | $3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
APLS APELLIS PHARMACEUTICALS INC | 0.06% | $40.23 | $40.23 | 0.0% | $3.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OM OUTSET MEDICAL INC | 0.06% | $11.06 | $3.00 | -72.9% | $2.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EDSA EDESA BIOTECH INC | 0.06% | $5.23 | $4.21 | -19.5% | $2.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ADPT ADAPTIVE BIOTECHNOLOGIES | 0.04% | $13.88 | $28.90 | +108.2% | $4.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AVTX AVALO THERAPEUTICS INC | 0.04% | $8.01 | $15.33 | +91.4% | $2.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CNTB CONNECT BIOPHARMA HOLDINGS L | 0.04% | $2.82 | $1.10 | -61.0% | $872K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CORT CORCEPT THERAPEUTICS INC | 0.04% | $40.31 | $115.23 | +185.9% | $5.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MDLN MEDLINE INC-CL A | 0.02% | $42.00 | $34.70 | -17.4% | $971.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PTN PALATIN TECHNOLOGIES INC | 0.02% | $15.38 | $8.87 | -42.3% | $549.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CPIX CUMBERLAND PHARMACEUTICALS | 0.01% | $3.98 | $3.24 | -18.6% | $638.2K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RVMDW REVOLUTION MEDICINES INC-28 | 0.01% | $0.33 | $11.44 | +3,366.7% | $2.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
XGN EXAGEN INC | 0.01% | $3.00 | $8.13 | +171.0% | $934.1K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ENSC ENSYSCE BIOSCIENCES INC | 0.00% | $8.14 | $0.42 | -94.9% | $36K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SRZNW SURROZEN INC-CW25 | 0.00% | — | $0.02 | — | $2.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
Average cost is an estimate, not the investor's actual purchase price: every quarter the share count rose, the added shares are counted at that quarter-end's 13F price, and sales keep the average. Latest price is the most recent 13F quarter-end price (Sep 30, 2026), and value is shares × latest price. * Held since before Mar 31, 2016, when our collected history starts, so the average starts from that quarter's price.
Changes in shares
Change in shares held vs Dec 31, 2025, for the 20 largest positions that changed. Bars are capped at ±100%; the label shows the actual change.
Sold out this quarter
Held on Dec 31, 2025 and not reported for Q1 2026.
| Stock | Prior weight | Prior shares | Prior value | Change |
|---|---|---|---|---|
| XBIPut SS SPDR S&P BIOTECH ETF | 2.39% | 1,100,000 | $134.1M | EXIT |
| EXAS EXACT SCIENCES CORP | 2.17% | 1,200,487 | $121.9M | EXIT |
| ACLX ARCELLX INC | 1.70% | 1,466,071 | $95.6M | EXIT |
| BSX BOSTON SCIENTIFIC CORP | 1.66% | 979,000 | $93.3M | EXIT |
| FOLD AMICUS THERAPEUTICS INC | 1.62% | 6,370,851 | $90.7M | EXIT |
| ATXS ASTRIA THERAPEUTICS INC | 1.51% | 6,485,420 | $84.9M | EXIT |
| DHR DANAHER CORP | 0.82% | 200,000 | $45.8M | EXIT |
| CDTX CIDARA THERAPEUTICS INC | 0.65% | 165,131 | $36.5M | EXIT |
| IRON DISC MEDICINE INC | 0.64% | 450,743 | $35.8M | EXIT |
| PEN PENUMBRA INC | 0.61% | 110,529 | $34.4M | EXIT |
| CAI CARIS LIFE SCIENCES INC | 0.55% | 1,136,206 | $30.7M | EXIT |
| RAPT RAPT THERAPEUTICS INC | 0.50% | 825,890 | $28M | EXIT |
| PVLA PALVELLA THERAPEUTICS INC | 0.50% | 266,287 | $27.9M | EXIT |
| KOD KODIAK SCIENCES INC | 0.42% | 848,900 | $23.7M | EXIT |
| BIIB BIOGEN INC | 0.39% | 124,000 | $21.8M | EXIT |
| ALDX ALDEYRA THERAPEUTICS INC | 0.39% | 4,185,632 | $21.7M | EXIT |
| MIRM MIRUM PHARMACEUTICALS INC | 0.37% | 259,545 | $20.5M | EXIT |
| GRAL GRAIL INC | 0.36% | 237,342 | $20.3M | EXIT |
| CVS CVS HEALTH CORP | 0.31% | 220,000 | $17.5M | EXIT |
| GKOS GLAUKOS CORP | 0.28% | 140,000 | $15.8M | EXIT |
| DXCM DEXCOM INC | 0.27% | 225,758 | $15M | EXIT |
| SVRA SAVARA INC | 0.26% | 2,400,000 | $14.5M | EXIT |
| SEPN SEPTERNA INC | 0.22% | 433,160 | $12.1M | EXIT |
| 38341P102 GOSSAMER BIO INC | 0.17% | 3,139,669 | $9.7M | EXIT |
| MPLT MAPLIGHT THERAPEUTICS INC | 0.17% | 550,000 | $9.7M | EXIT |
| XENE XENON PHARMACEUTICALS INC | 0.16% | 200,791 | $9M | EXIT |
| KMTS KESTRA MEDICAL TECHNOLOGIES | 0.13% | 285,000 | $7.6M | EXIT |
| CAPRCall CAPRICOR THERAPEUTICS INC | 0.12% | 242,100 | $7M | EXIT |
| BHVNCall BIOHAVEN LTD | 0.10% | 500,000 | $5.6M | EXIT |
| KYMR KYMERA THERAPEUTICS INC | 0.10% | 69,935 | $5.4M | EXIT |
| PEPG PEPGEN INC | 0.10% | 829,870 | $5.4M | EXIT |
| TECXCall TECTONIC THERAPEUTIC INC | 0.09% | 250,000 | $5.2M | EXIT |
| AQST AQUESTIVE THERAPEUTICS INC | 0.09% | 747,193 | $4.8M | EXIT |
| KRYS KRYSTAL BIOTECH INC | 0.08% | 17,500 | $4.3M | EXIT |
| OLMA OLEMA PHARMACEUTICALS INC | 0.07% | 165,713 | $4.1M | EXIT |
| SDGR SCHRODINGER INC | 0.06% | 202,400 | $3.6M | EXIT |
| IMMX IMMIX BIOPHARMA INC | 0.03% | 338,941 | $1.8M | EXIT |
| LXEO LEXEO THERAPEUTICS INC | 0.02% | 139,835 | $1.4M | EXIT |
| LENZ LENZ THERAPEUTICS INC | 0.01% | 50,000 | $800K | EXIT |
| BDSX BIODESIX INC | 0.01% | 108,694 | $739.1K | EXIT |
| 29415J106 ENVVENO MEDICAL CORPORATION | 0.01% | 1,759,035 | $564.3K | EXIT |
| IOVA IOVANCE BIOTHERAPEUTICS INC | 0.01% | 152,714 | $416.9K | EXIT |
SEC filings for Q1 2026
- 13F-HR 0001012975-26-000443 · accepted May 15, 2026, 20:10 UTC
- 13F-HR/A 0001012975-26-000499 · accepted May 29, 2026, 15:41 UTC · RESTATEMENT